PURPOSE: To determine the effectiveness of weekend atropine for severe amblyopia from strabismus, anisometropia, or both combined among children 3 to 12 years of age. METHODS: We enrolled children into 2 prospective, randomized multicenter clinical trials of amblyopia therapy. Herein we report the results for severe amblyopia, 20/125 to 20/400. In Trial 1, 60 children 3 to 6 years of age (mean, 4.4 years) were randomized to weekend atropine plus a plano lens or weekend atropine plus full spectacle correction for the sound eye. In Trial 2, 40 children 7 to 12 years of age (mean, 9.3 years) were randomized to weekend atropine or 2 hours of daily patching. The visual acuity outcome was assessed at 18 weeks in Trial 1 and 17 weeks in Trial 2. RESULTS: In Trial 1, visual acuity improved by an average of 4.5 lines in the atropine plus correction group (95% CI, 3.2-5.8 lines) and 5.1 lines in the atropine plus plano lens group (95% CI, 3.7-6.4 lines). In Trial 2, visual acuity improved by an average of 1.5 lines in the atropine group (95% CI, 0.5-2.5 lines) and 1.8 lines in the patching group (95% CI, 1.1-2.6 lines). CONCLUSIONS:Weekend atropine can improve visual acuity in children 3 to 12 years of age with severe amblyopia. Improvement may be greater in younger children.
RCT Entities:
PURPOSE: To determine the effectiveness of weekend atropine for severe amblyopia from strabismus, anisometropia, or both combined among children 3 to 12 years of age. METHODS: We enrolled children into 2 prospective, randomized multicenter clinical trials of amblyopia therapy. Herein we report the results for severe amblyopia, 20/125 to 20/400. In Trial 1, 60 children 3 to 6 years of age (mean, 4.4 years) were randomized to weekend atropine plus a plano lens or weekend atropine plus full spectacle correction for the sound eye. In Trial 2, 40 children 7 to 12 years of age (mean, 9.3 years) were randomized to weekend atropine or 2 hours of daily patching. The visual acuity outcome was assessed at 18 weeks in Trial 1 and 17 weeks in Trial 2. RESULTS: In Trial 1, visual acuity improved by an average of 4.5 lines in the atropine plus correction group (95% CI, 3.2-5.8 lines) and 5.1 lines in the atropine plus plano lens group (95% CI, 3.7-6.4 lines). In Trial 2, visual acuity improved by an average of 1.5 lines in the atropine group (95% CI, 0.5-2.5 lines) and 1.8 lines in the patching group (95% CI, 1.1-2.6 lines). CONCLUSIONS: Weekend atropine can improve visual acuity in children 3 to 12 years of age with severe amblyopia. Improvement may be greater in younger children.
Authors: J M Holmes; R W Beck; M X Repka; D A Leske; R T Kraker; R C Blair; P S Moke; E E Birch; R A Saunders; R W Hertle; G E Quinn; K A Simons; J M Miller Journal: Arch Ophthalmol Date: 2001-09
Authors: Stephen B Kaye; Sean I Chen; Gary Price; Lesley C Kaye; Carmel Noonan; Ajay Tripathi; Pammal Ashwin; Nolan Cota; David Clark; Jeremy Butcher Journal: J AAPOS Date: 2002-10 Impact factor: 1.220
Authors: Mitchell M Scheiman; Richard W Hertle; Roy W Beck; Allison R Edwards; Eileen Birch; Susan A Cotter; Earl R Crouch; Oscar A Cruz; Bradley V Davitt; Sean Donahue; Jonathan M Holmes; Don W Lyon; Michael X Repka; Nicholas A Sala; David I Silbert; Donny W Suh; Susanna M Tamkins Journal: Arch Ophthalmol Date: 2005-04
Authors: Michael X Repka; Susan A Cotter; Roy W Beck; Raymond T Kraker; Eileen E Birch; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Nicholas A Sala; Mitchell M Scheiman; David R Stager; David K Wallace Journal: Ophthalmology Date: 2004-11 Impact factor: 12.079
Authors: Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman Journal: Arch Ophthalmol Date: 2003-05
Authors: Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker Journal: Am J Ophthalmol Date: 2003-02 Impact factor: 5.258
Authors: Mitchell M Scheiman; Richard W Hertle; Raymond T Kraker; Roy W Beck; Eileen E Birch; Joost Felius; Jonathan M Holmes; James Kundart; David G Morrison; Michael X Repka; Susanna M Tamkins Journal: Arch Ophthalmol Date: 2008-12
Authors: Michael X Repka; Raymond T Kraker; Roy W Beck; Eileen Birch; Susan A Cotter; Jonathan M Holmes; Richard W Hertle; Darren L Hoover; Deborah L Klimek; Wendy Marsh-Tootle; Mitchell M Scheiman; Donny W Suh; David R Weakley Journal: J AAPOS Date: 2009-10-01 Impact factor: 1.220